Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6865274 | 0.76 | HMGCR (0.38) | EPHX2ALDH1A1KDM4EHTTHSD17B10 | |
| SCHEMBL6864589 | 0.72 | ALDH1A1 (0.37) | EPHX2ALDH1A1EPHX1KDM4EHTT | |
| SCHEMBL4933401 | 0.68 | ALDH1A1 (0.38) | SMN1; SMN2ALDH1A1EPHX1NPC1KMT2A | |
| SCHEMBL7459280 | 0.66 | SLC22A2 (0.39) | EPHX2ALDH1A1EPHX1NPC1KMT2A | |
| SCHEMBL6865266 | 0.66 | POLB (0.36) | ALDH1A1TSHR | |
| SCHEMBL13609148 | 0.65 | EPHX2 (0.38) | EPHX2NPSR1ALDH1A1NPC1KMT2A | |
| SCHEMBL26939367 | 0.65 | SMN1; SMN2 (0.36) | SMN1; SMN2EPHX2NPSR1ALDH1A1EPHX1 | |
| SCHEMBL9608695 | 0.65 | ALDH1A1 (0.36) | SMN1; SMN2EPHX2ALDH1A1KMT2A | |
| SCHEMBL4990698 | 0.65 | THRB (0.38) | EPHX2ALDH1A1EPHX1NPC1KMT2A | |
| SCHEMBL5969137 | 0.65 | SLC22A2 (0.38) | EPHX2ALDH1A1EPHX1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170128489-A1 | ORGANO-TRANSITION METAL COMPLEXES FOR THE TREATMENT OF VIRAL INFECTIONS | BRIGHAM YOUNG UNIVERSITY (US) | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128489-A1 | ORGANO-TRANSITION METAL COMPLEXES FOR THE TREATMENT OF VIRAL INFECTIONS | HVCN1, TRPM8, TRPM2 | SMN1; SMN2 3622/4885EPHX2 4833/4885NPSR1 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.